Logo image of NBSE

NEUBASE THERAPEUTICS INC (NBSE) Stock Fundamental Analysis

USA - NASDAQ:NBSE - US64132K2015 - Common Stock

0.378 USD
-0.01 (-3.2%)
Last: 5/10/2024, 8:08:45 PM
0.42 USD
+0.04 (+11.11%)
After Hours: 5/10/2024, 8:08:45 PM
Fundamental Rating

2

Taking everything into account, NBSE scores 2 out of 10 in our fundamental rating. NBSE was compared to 534 industry peers in the Biotechnology industry. The financial health of NBSE is average, but there are quite some concerns on its profitability. NBSE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NBSE has reported negative net income.
In the past year NBSE had a positive cash flow from operations.
NBSE had negative earnings in each of the past 5 years.
In the past 5 years NBSE always reported negative operating cash flow.
NBSE Yearly Net Income VS EBIT VS OCF VS FCFNBSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

NBSE has a Return On Assets of -73.74%. This is in the lower half of the industry: NBSE underperforms 69.40% of its industry peers.
The Return On Equity of NBSE (-150.22%) is worse than 65.98% of its industry peers.
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROIC N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
NBSE Yearly ROA, ROE, ROICNBSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

NBSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBSE Yearly Profit, Operating, Gross MarginsNBSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

NBSE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NBSE has more shares outstanding
NBSE has a better debt/assets ratio than last year.
NBSE Yearly Shares OutstandingNBSE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
NBSE Yearly Total Debt VS Total AssetsNBSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NBSE has an Altman-Z score of -10.48. This is a bad value and indicates that NBSE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NBSE (-10.48) is worse than 78.97% of its industry peers.
There is no outstanding debt for NBSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -10.48
ROIC/WACCN/A
WACCN/A
NBSE Yearly LT Debt VS Equity VS FCFNBSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

NBSE has a Current Ratio of 2.87. This indicates that NBSE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NBSE (2.87) is worse than 68.03% of its industry peers.
NBSE has a Quick Ratio of 2.87. This indicates that NBSE is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.87, NBSE is not doing good in the industry: 66.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
NBSE Yearly Current Assets VS Current LiabilitesNBSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

NBSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.05%, which is quite impressive.
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.88% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBSE Yearly EPS VS EstimatesNBSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NBSE. In the last year negative earnings were reported.
Also next year NBSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBSE Price Earnings VS Forward Price EarningsNBSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

NBSE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBSE is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 0.1
EV/EBITDA N/A
NBSE Per share dataNBSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

NBSE's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.21%
EPS Next 3Y21.21%

More info and screens

0

5. Dividend

5.1 Amount

NBSE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUBASE THERAPEUTICS INC

NASDAQ:NBSE (5/10/2024, 8:08:45 PM)

After market: 0.42 +0.04 (+11.11%)

0.378

-0.01 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2024-05-13
Earnings (Next)08-12 2024-08-12
Inst Owners3.64%
Inst Owner Change0%
Ins Owners12.28%
Ins Owner Change0%
Market Cap1.42M
Revenue(TTM)N/A
Net Income(TTM)-13730000
Analysts43.33
Price Target142.8 (37677.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.15%
Min EPS beat(2)-2.3%
Max EPS beat(2)0%
EPS beat(4)2
Avg EPS beat(4)10.77%
Min EPS beat(4)-2.3%
Max EPS beat(4)30.42%
EPS beat(8)4
Avg EPS beat(8)4.45%
EPS beat(12)6
Avg EPS beat(12)1.88%
EPS beat(16)8
Avg EPS beat(16)-38.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 0.1
P/OCF 0.1
P/B 0.16
P/tB 0.16
EV/EBITDA N/A
EPS(TTM)-7.3
EYN/A
EPS(NY)-9.18
Fwd EYN/A
FCF(TTM)3.9
FCFY1032.8%
OCF(TTM)3.79
OCFY1003.88%
SpS0
BVpS2.44
TBVpS2.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr -683.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.87
Altman-Z -10.48
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)226.06%
Cap/Depr(5y)214.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y213.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y219.18%
OCF growth 3YN/A
OCF growth 5YN/A